Amicogen Inc Asset Resilience Ratio
Amicogen Inc asset resilience ratio. Amicogen Inc (092040) has an Asset Resilience Ratio of 0.50% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 092040 cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Amicogen Inc (2014–2025)
Asset resilience ratio of Amicogen Inc from 2014 to 2025. This chart shows how Amicogen Inc's Asset Resilience Ratio has changed over time. Read 092040 total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Amicogen Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is Amicogen Inc's balance sheet.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩1.07 Billion | 0.5% |
| Total Liquid Assets | ₩1.07 Billion | 0.50% |
Asset Resilience Insights
- Limited Liquidity: Amicogen Inc maintains only 0.50% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Amicogen Inc Industry Peers by Asset Resilience Ratio
Compare Amicogen Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Viatris Inc
NASDAQ:VTRS |
Drug Manufacturers - Specialty & Generic | 1.48% |
|
Tianjin Zhongxin Pharmaceutical Group Corp Ltd
SHG:600329 |
Drug Manufacturers - Specialty & Generic | 5.92% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Curaleaf Holdings Inc.
TO:CURA |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026 |
Drug Manufacturers - Specialty & Generic | -0.89% |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550 |
Drug Manufacturers - Specialty & Generic | 18.70% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Harbin Gloria Pharmaceuticals
SHE:002437 |
Drug Manufacturers - Specialty & Generic | 9.04% |
Amicogen Inc Asset Resilience Ratio by Year (2014–2025)
Amicogen Inc asset resilience ratio by year from 2014 to 2025. The table below shows the annual Asset Resilience Ratio data for Amicogen Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.43% | ₩1.00 Billion ≈ $679.59K |
₩231.86 Billion ≈ $157.13 Million |
-2.64pp |
| 2024-12-31 | 3.07% | ₩9.03 Billion ≈ $6.12 Million |
₩294.23 Billion ≈ $199.39 Million |
-5.18pp |
| 2023-12-31 | 8.25% | ₩38.54 Billion ≈ $26.12 Million |
₩467.10 Billion ≈ $316.55 Million |
+2.74pp |
| 2022-12-31 | 5.51% | ₩23.68 Billion ≈ $16.05 Million |
₩429.65 Billion ≈ $291.17 Million |
-4.83pp |
| 2021-12-31 | 10.34% | ₩42.52 Billion ≈ $28.81 Million |
₩411.22 Billion ≈ $278.68 Million |
-5.19pp |
| 2020-12-31 | 15.53% | ₩43.99 Billion ≈ $29.81 Million |
₩283.37 Billion ≈ $192.03 Million |
+4.56pp |
| 2019-12-31 | 10.97% | ₩26.47 Billion ≈ $17.94 Million |
₩241.40 Billion ≈ $163.59 Million |
+4.57pp |
| 2018-12-31 | 6.40% | ₩14.79 Billion ≈ $10.02 Million |
₩231.21 Billion ≈ $156.69 Million |
-7.19pp |
| 2017-12-31 | 13.58% | ₩22.21 Billion ≈ $15.05 Million |
₩163.51 Billion ≈ $110.81 Million |
+3.86pp |
| 2016-12-31 | 9.73% | ₩14.23 Billion ≈ $9.65 Million |
₩146.33 Billion ≈ $99.17 Million |
+3.00pp |
| 2015-12-31 | 6.73% | ₩10.76 Billion ≈ $7.29 Million |
₩159.84 Billion ≈ $108.32 Million |
-2.67pp |
| 2014-12-31 | 9.40% | ₩5.11 Billion ≈ $3.46 Million |
₩54.37 Billion ≈ $36.84 Million |
-- |
About Amicogen Inc
Amicogen, Inc. operates as an industrial biotechnology company in South Korea and internationally. The company develops, produces, and sells of enzymes and new materials; and produces food-related additives and health functional food. It manufactures and sells of biopharmaceutical materials and resins for purifying pharmaceutical proteins and health and beauty products. In addition, the company o… Read more